Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a Healthcare company (Biotechnology) with a market capitalization of $793M. The Maz Rating grades it against the other companies in its sector.
Lexicon Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.78, Lexicon Pharmaceuticals, Inc. trades at 20.6x sales and 4.8x book value. Over the last twelve months it generated about $38M of revenue and a net loss of $65M. It runs a gross margin of 98.6%, an operating margin of -147.4% and a net margin of -161.8%. It shows return on equity of -38.4%, return on invested capital of -25.1% and a free cash flow yield of -8.0%. On the balance sheet: a debt-to-equity ratio of 0.36 and a current ratio of 10.63. Over the past 52 weeks the share price ranged from $1.10 to $2.68, with a beta of 1.08.
Lexicon Pharmaceuticals, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 5 Buy, 7 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Lexicon Pharmaceuticals, Inc. (LXRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 6.30% / 30% · (Cash+Inv) / Mkt Cap (36m) 22.2% / 30% · Interest income / Revenue 14.4% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 6.30% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 22.2% / 33% · Receivables / Mkt Cap (36m) 0.22% / 49% · Interest income / Revenue 14.4% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 6.30% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 22.2% / 33.33% · Receivables / Mkt Cap (24m) 0.22% / 33.33% · Interest income / Revenue 14.4% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 22.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 67.7% / 33.33% · Receivables / Avg Assets (4Q) 1.86% / 33.33% · Interest income / Revenue 14.4% / 5% | Fail |
| FTSE | Debt / Total Assets 21.4% / 33.33% · (Cash+ST Inv) / Total Assets 75.7% / 33.33% · (Cash+Recv) / Total Assets 76.4% / 33.33% · Interest income / Revenue 14.4% / 5% | Fail |
No. As of September 2026, Lexicon Pharmaceuticals, Inc. (LXRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Lexicon Pharmaceuticals, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 14.4% of each dividend: Lexicon Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.